West Pharmaceutical (NYSE: WST) director awarded 791 restricted stock units in equity grant

Rhea-AI Filing Summary

WEST PHARMACEUTICAL SERVICES INC director receives stock award. Director Douglas A. Michels acquired 791 shares of common stock as a grant or award, recorded at a price of $0.00 per share, reflecting equity compensation rather than a market purchase.

These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributable under the company’s Deferred Compensation Plan for Outside Directors. After this grant, Michels directly holds 46,495.55 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Michels Douglas A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	791	$0.00	--

Holdings After Transaction: Common Stock — 46,495.55 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 791 shares Post-transaction holdings: 46,495.55 shares Transaction date: 2026-05-04 +1 more

4 metrics

Equity grant size 791 shares Restricted stock units granted to director on transaction date

Post-transaction holdings 46,495.55 shares Total common stock held directly by Michels after grant

Transaction date 2026-05-04 Date of restricted stock unit grant reported on Form 4

Vesting condition Next annual shareholder meeting Restricted stock units vest in full on this meeting date

Key Terms

restricted stock units, Deferred Compensation Plan for Outside Directors, annual shareholder meeting

3 terms

restricted stock units financial

"These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Deferred Compensation Plan for Outside Directors financial

"and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors"

annual shareholder meeting regulatory

"will vest in full on the date of the next annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Michels Douglas A

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		791(1)	A	$0	46,495.55	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

	/s/ Louis Lalli, as an agent for Douglas A. Michels	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did WST director Douglas A. Michels report?

Douglas A. Michels reported receiving 791 shares of WEST PHARMACEUTICAL SERVICES INC common stock as a grant or award. The shares are structured as restricted stock units that form part of his equity compensation as an outside director, not as an open-market stock purchase.

How many WEST PHARMACEUTICAL (WST) shares did Michels hold after this grant?

After the reported grant, Douglas A. Michels held 46,495.55 shares of WEST PHARMACEUTICAL SERVICES INC common stock directly. This total includes the newly granted 791 restricted stock units, which are scheduled to vest at the company’s next annual shareholder meeting.

What type of equity award did WST grant to director Douglas A. Michels?

Douglas A. Michels received 791 restricted stock units of WEST PHARMACEUTICAL SERVICES INC common stock. Restricted stock units are share-based awards that generally vest over time or upon specific events, aligning director compensation with long-term shareholder interests while delaying actual share distribution.

When will Douglas A. Michels’ WST restricted stock units vest and be distributed?

The 791 restricted stock units granted to Douglas A. Michels will vest in full on the date of WEST PHARMACEUTICAL SERVICES INC’s next annual shareholder meeting. They will then be distributable under the company’s Deferred Compensation Plan for Outside Directors, according to the plan’s terms.

Was the WST insider transaction a market buy or a compensation grant?

The WST insider transaction was a compensation-related grant, not a market buy. Douglas A. Michels received 791 shares at a stated price of $0.00 per share as a grant or award, consistent with non-cash equity compensation for his role as an outside director.

What is the Deferred Compensation Plan for Outside Directors at WEST PHARMACEUTICAL?

The Deferred Compensation Plan for Outside Directors is the program under which Michels’ restricted stock units will be distributed. It governs how and when outside directors receive share-based awards, allowing vesting at the next annual shareholder meeting and deferred delivery of the underlying common stock.